Ramaphosa welcomes US U-turn on vaccine patents, which may allow SA to ramp up production

accreditation
0:00
play article
Subscribers can listen to this article
President Cyril Ramaphosa.
President Cyril Ramaphosa.
GCIS
  • President Cyril Ramaphosa has welcomed the US decision to support a temporary patent waiver on Covid-19 vaccines.
  • This is a sharp reversal from the country's previous position, but a US trade representative said that the pandemic called for "extraordinary" measures.
  • If the World Trade Organization agrees to the waiver, it could mean that pharmaceutical producers in South Africa could make generic versions of the Covid-19 vaccines.


President Cyril Ramaphosa has welcomed the US decision to support a temporary patent waiver on Covid-19 vaccines.

Currently only pharmaceutical companies that own the patents for the vaccines are allowed to manufacture the jabs. But lifting the patent rights means that they will lose this exclusive right. Their formulas can then be used by other companies who have the required technology to manufacture generic versions of these vaccines, without fear that they will be sued.

Potentially, this means that vaccines can be manufactured at much greater scale in South Africa, and in other countries.

US support for the waiver comes as a surprise, as it is a sharp reversal of its previous position.

"This is a global health crisis," Katherine Tai, a US trade representative, said in a written statement. "The extraordinary circumstances of the Covid-19 pandemic call for extraordinary measures."

The European Union still opposes the waiver, but US support should help to secure the necessary consensus at forthcoming World Trade Organization negotiations.

In a statement, Ramaphosa said the negotiations "provide the global community, and especially leading economies, with both an opportunity and the challenge to act in the best interest of all humanity".

"This can be achieved by focusing on the moral, legal and economic benefits of providing urgent, affordable and equitable protection to all people around the world in the face of a grave and indiscriminate threat to life and economic sustainability.  In light of the growing global consensus, we call on pharmaceutical companies to facilitate sharing of know-how and technology to enable a rapid increase in supply-capacity in order to save lives."

South Africa and India have been campaigning for the waiver since last year.

"For countries that do not currently have manufacturing capacity on certain medical technologies, the waiver could open up more supply options and avoid countries being reliant on only one or two suppliers," Ramaphosa said in a statement. "Where supply capacity currently exists, it can be repurposed to Covid-19 vaccine production and in this way improve the supply available to all nations."

He welcomed the US's support of "a temporary and targeted waiver" of intellectual property protections that apply to the vaccines. 

The share prices of big pharmaceutical companies including Pfizer, BioNTech Novavax and CureVac declined following the US decision. 

Get the biggest business stories emailed to you every weekday.

Go to the Fin24 front page.

We live in a world where facts and fiction get blurred
In times of uncertainty you need journalism you can trust. For only R75 per month, you have access to a world of in-depth analyses, investigative journalism, top opinions and a range of features. Journalism strengthens democracy. Invest in the future today.
Subscribe to News24
Rand - Dollar
14.23
+0.5%
Rand - Pound
19.82
-0.4%
Rand - Euro
16.96
-0.1%
Rand - Aus dollar
10.72
-0.3%
Rand - Yen
0.13
+0.4%
Gold
1,783.08
+1.1%
Silver
26.00
+0.7%
Palladium
2,564.50
+3.9%
Platinum
1,054.01
+1.5%
Brent Crude
73.51
+0.6%
Resource 10
61,142
+0.3%
Industrial 25
87,978
+0.0%
Financial 15
12,871
-1.0%
Top 40
59,472
-0.1%
All Share
65,564
-0.1%
All JSE data delayed by at least 15 minutes Iress logo
Company Snapshot
Voting Booth
Should government have assigned a majority shareholding in SAA to the private sector?
Please select an option Oops! Something went wrong, please try again later.
Results
Yes, It's a good decision
65% - 233 votes
Not a good move
10% - 34 votes
Too early to tell
25% - 89 votes
Vote